Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹543 Cr
verified against source
Revenue YoY
10.6%
reported change
EBITDA
Pending
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Caplin Point reported a steady Q3 FY26 with 10.6% YoY revenue growth and 28.3% PAT margin, driven by strong US sterile injectable approvals and disciplined cost management. The US label business has reached nearly $10M in cumulative revenue since inception, with a 75:25 mix of product and milestone income. Management highlighted a consolidation phase over the next 18-24 months as new markets (Mexico, Chile) and oncology injectables ramp up. Key growth drivers include 14-15 injectable lines coming online, a new blow-fill-seal capability, and video SOPs to enhance compliance. Risks include potential delays in oncology facility commercialization and slower-than-expected ramp-up in new Latin American markets.
Colored figures show movement against the previous available record.
Guidance to track
- Expect high double-digit revenue growth in the next years for Caplin Steriles and Caplin USA.
- Expect to complete at least 12-13 products in ophthalmic and prefilled syringe range within next 12 months, coming up for approval by end of next year.
- Targeting first DMF filing from Vizag API plant by end of this year, with 2-3 more APIs scaled up monthly.
- Management expects PAT margin to stay in the 26-29% path, with potential for improvement as new initiatives fire.
Risks flagged
- Oncology injectable plant has been delayed from Q1 FY27 to Q3 FY27 due to ecosystem challenges in Tamil Nadu, potentially impacting revenue timelines.
- Despite doubling fixed assets in 2.5-3 years, top line grew only 40-50%, raising concerns about asset turnover and return on capex.
- Mexico and Chile markets are still 18-24 months away from meaningful revenue contribution, with tender-heavy dynamics and regulatory hurdles.
- GLP-1 market in developing regions is nascent; management admits being in the 'second wave' and the space is 'unknown' with unclear adoption.
Key quotes
- Our video SOP will convert invisible execution into inspectable evidence for compliance.
- We are not in the domestic market where the minute you come up with a product you can directly go and then start making sales... things take at least 3 to four years for some amount of gaining maturity.
- We are very pleasantly surprised with the progress that we are making with our US label. We are nearly at $10 million in revenue since inception last year.
Research modules